VANCOUVER, BC / ACCESSWIRE / February 4, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the "Company") a biotechnology research and development company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy is pleased to announce it has entered into a letter of intent (the "Letter of Intent") dated January 20, 2021 with Ketamine Infusion Centers of Texas, LLC ("KICT"), an arms-length-party, to review a potential acquisition of KICT.
KICT is a Health and Wellness Clinic located in Woodlands, Texas that was established to address treatment-resistant depression and other mental health disorders, through the delivery of Ketamine infusion treatments. KICT aims to be known as a centre of excellence in the management of treatment-resistant depression and strives to achieve this by providing unparalleled and individualized care based on the uniqueness of eachclient. Using research-based data, KICT has created proven, effective treatment protocols that have helped patients suffering from treatment-resistant depression, as well as other mental health disorders. These include major depressive disorder, bipolar disorder, post-partum depression, post-traumatic stress disorder and obsessive compulsive disorder.
"The acquisition of KICT poses an exciting growth opportunity for Core One as we endeavour to broaden our footprint in the psychedelics as alternative medicines' market and expand our presence in medical clinics across North America. It is our first step into the leading psychedelic treatment methodology in the US which opens up a whole new market for us" stated Joel Shaker, CEO of the Company.
"KICT's history as established practitioners in this burgeoning field, and Core One's ongoing research and development in alternative psychedelic medicines and delivery methods, create a unique and international platform to address mental health. This acquisition is the first step in building our foundation and infrastructure in the US, where regulations surrounding psychedelics are shifting rapidly. Given KICT's cutting edge treatment approach and client base, Core One is positioned to take advantage of a variety of new treatment options that are going through the FDA process. Furthermore, this provides us with an impressive avenue to conduct research and clinical trials to create additional novel IP."
ABOUT KETAMINE
Ketamine is a legal drug and at a sub-anesthetic dose produces a non-ordinary state of consciousness that produces psychedelic and euphoric effects. Ketamine is showing much success in providing symptom relief for depression, anxiety, and other mental health conditions when administered in conjunction with psychotherapy.
In 2000 Yale University published the first study on Ketamine's use for the treatment of depression. Since this first study many subsequent studies have been published, providing evidence of the safety and efficacy of Ketamine, as an alternative treatment method. The use of Ketamine has been so effective that Dr. Thomas Insel, Director of the National Institutes of Health stated, "Recent data suggest that Ketamine, given intravenously, may be the most important breakthrough in antidepressant treatment in decades".
According to the World Health Organization, 300 million people worldwide have depression. 16.2 million Americans or roughly 7% have experienced depression in the past year. 10.3 million Americans have experienced an episode that has caused severe impairment including loss of jobs and relationships. Depression is the leading cause of disability worldwide. The total economic burden is estimated to be $210 billion annually.
"There are many facets of depression including bipolar disorders, anxiety disorders, and post-traumatic stress disorder (PTSD). We all have been affected by depression in one way or another. Many of us witnessing firsthand what depression can do to a loved one, a close friend, or work colleague. Depression can create an incredible void in these individuals, yet unfortunately, depression and the field of mental health has taken a back seat in our present day culture. Unlike diagnoses such as hypertension, coronary artery disease, or diabetes, depression is not a condition that is well accepted by society and causes people with this disorder to withdraw even further away, shutting out the world around them," stated Michael Nguyen, M.D., Psy.D., Medical Director of KICT.
LETTER OF INTENT TERMS
Pursuant to the terms of the Letter of Intent, it is contemplated that the Company would acquire all of the outstanding membership interests in KICT in consideration for US$200,000, which would be satisfied through the issuance of common shares of the Company upon closing.
Completion of the acquisition of KICT is subject to a number of conditions, including, but not limited to, completion of due diligence, negotiation of definitive documentation and the receipt of any required regulatory approvals. The proposed acquisition is not expected to constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange.
ABOUT CORE ONE LABS INC.
Core One Labs Inc. is a biotechnology research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The Company has developed a patent pending thin film oral strip (the "technology") which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. With this technology, the Company intends to further develop its IP technology to focus on delivering psychedelic molecules with an initial focus on psilocybin. Core One also holds an interest in walk-in medical clinics which maintain a database of over 200,000 patients combined. Through research and development in these clinics, including the integration of its intellectual property related to psychedelic treatments and novel drug therapies, the Company intends to work towards regulatory approval for research that advances psychedelic-derived treatments for mental health disorders.
Core One Labs Inc.Joel ShackerChief Executive Officer
FOR MORE INFORMATION, PLEASE CONTACT:
info@core1labs.com1-866-347-5058
Cautionary Disclaimer Statement:
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with environmental and governmental regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription. Health Canada has not approved psilocybin as a drug for any indication. Core One Labs Inc. does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One Labs Inc. believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One Labs Inc. does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.
SOURCE: Core One Labs Inc.
View source version on accesswire.com:https://www.accesswire.com/627856/Core-One-Labs-Announces-Its-Entrance-into-the-Ketamine-Space-with-Proposed-Acquisition-of-Ketamine-Infusion-Centers-of-Texas
View post:
- 8 Mystical Herbs and Legal Psychedelics For Lucid Dreaming - December 8th, 2016 [December 8th, 2016]
- Psychedelics: LSD, Mushrooms, Salvia | Facts | Drug Policy ... - December 10th, 2016 [December 10th, 2016]
- FS Book Company - Marijuana Books - December 12th, 2016 [December 12th, 2016]
- Psychedelic - PsychonautWiki - December 27th, 2016 [December 27th, 2016]
- From Alzheimer's To Psychedelics, 2016 Was A Good Year For ... - January 3rd, 2017 [January 3rd, 2017]
- LSD - Psychedelic Effects - The Good Drugs Guide - January 5th, 2017 [January 5th, 2017]
- THC - Psychedelics - January 29th, 2017 [January 29th, 2017]
- Psychedelics | Pharmacological Reviews - January 30th, 2017 [January 30th, 2017]
- Dorian Yates reveals all on steroids, body dysmorphia, psychedelics, cannabis and yoga - Express.co.uk - February 7th, 2017 [February 7th, 2017]
- Psychedelic drug therapy including magic mushrooms, LSD and ... - CBS News - February 7th, 2017 [February 7th, 2017]
- Psychedelics Being Tested For Use In Treating Various Conditions - CBS Local - February 8th, 2017 [February 8th, 2017]
- The psychedelic renaissance - Boulder Weekly - February 9th, 2017 [February 9th, 2017]
- Buy psychedelics online : Chinglabs.com - February 12th, 2017 [February 12th, 2017]
- Psychedelic drugs like magic mushrooms and LSD have key ... - Yahoo Finance - February 13th, 2017 [February 13th, 2017]
- Psychedelics a Viable Therapeutic Option for Depression - Psychiatry Advisor - February 14th, 2017 [February 14th, 2017]
- Is Silicon Valley Onto Something With Its LSD Microdosing? - Newsweek - February 15th, 2017 [February 15th, 2017]
- News Releases - Noozhawk - February 16th, 2017 [February 16th, 2017]
- A Revolution in the Science of Psychedelics is Happening in Boulder - 303 Magazine - February 16th, 2017 [February 16th, 2017]
- When Reality Is More Intense Than Psychedelics: Strand Of Oaks ... - NPR - February 17th, 2017 [February 17th, 2017]
- Psychedelics Help Reduce Opioid Addiction, According to New Study - AlterNet - February 22nd, 2017 [February 22nd, 2017]
- Psychedelics May Help Reduce Opioid Addiction, According To ... - Huffington Post - February 23rd, 2017 [February 23rd, 2017]
- Psychedelics Help Reduce Opioid Addiction, According to New Study - eNews Park Forest - February 24th, 2017 [February 24th, 2017]
- Psychedelics Could Play A Role In Tackling The Opioid Epidemic - Huffington Post - February 24th, 2017 [February 24th, 2017]
- Meet The People's Champion of Psychedelic Drugs - Narratively - February 27th, 2017 [February 27th, 2017]
- How psychedelics like psilocybin and LSD actually change the way ... - Yahoo Finance - February 27th, 2017 [February 27th, 2017]
- First U. student group on studying psychedelics holds open house - The Daily Princetonian - February 27th, 2017 [February 27th, 2017]
- How psychedelics like psilocybin and LSD actually change the way people see the world - Businessinsider India - February 28th, 2017 [February 28th, 2017]
- Psychedelics Help Reduce Opioid Addiction, According to New ... - February 28th, 2017 [February 28th, 2017]
- WATCH: A Public Policy Expert Explains How to Safely Deregulate LSD and Other Psychedelics - AlterNet - March 7th, 2017 [March 7th, 2017]
- Quotes About Psychedelics (48 quotes) - March 7th, 2017 [March 7th, 2017]
- Inside the Psychedelic Underground - RollingStone.com - March 9th, 2017 [March 9th, 2017]
- What Psychedelics Really Do to Your Brain - Rolling Stone - RollingStone.com - March 10th, 2017 [March 10th, 2017]
- Hallucinogens Help, According to a Mom's Memoir and Son's Documentary - Bedford + Bowery - April 8th, 2017 [April 8th, 2017]
- Meditation and the psychedelic drug ayahuasca seem to change the brain in surprisingly similar ways - Businessinsider India - April 8th, 2017 [April 8th, 2017]
- Tripping out: the highs and lows of psychedelic therapy - Marie Claire UK - April 8th, 2017 [April 8th, 2017]
- Stop Policing Psychedelic Science - Motherboard - June 6th, 2017 [June 6th, 2017]
- America's Trippiest Chemist: Making Psychedelics 'Was Fun' - Motherboard - June 6th, 2017 [June 6th, 2017]
- The Three Types of Hallucinogens: Psychedelics ... - June 7th, 2017 [June 7th, 2017]
- Cary Grant was one of the first to benefit from LSD therapy - Quartz - June 11th, 2017 [June 11th, 2017]
- What it's like to take psychedelics in small doses at breakfast - New Scientist - June 14th, 2017 [June 14th, 2017]
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - Religion News Service - June 14th, 2017 [June 14th, 2017]
- Q&A With Psychedelic Stand-Up and LaughFest Headliner Shane Mauss - Flagpole Magazine - June 20th, 2017 [June 20th, 2017]
- Q&A: LaughFest comedian talks science and psychedelics - Red and Black - June 20th, 2017 [June 20th, 2017]
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - The Daily Tribune - June 21st, 2017 [June 21st, 2017]
- Shane Mauss brings Good Trip Comedy Tour to town - Chattanooga Times Free Press - June 22nd, 2017 [June 22nd, 2017]
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - The Oakland Press - June 22nd, 2017 [June 22nd, 2017]
- Director Ana Lily Amirpour on Cannibalism, Psychedelics, and 'Horrifying' Racism Allegations - Jezebel - June 23rd, 2017 [June 23rd, 2017]
- Majority of Americans ready to embrace psychedelic therapy - YouGov US - June 24th, 2017 [June 24th, 2017]
- The Refugee Funding America's Psychedelic Renaissance - VICE - June 24th, 2017 [June 24th, 2017]
- Open Your Mind This Weekend at Europe's Largest Psychedelic Conference - VolteFace Magazine (blog) - June 27th, 2017 [June 27th, 2017]
- Psychedelics and Virtual Reality Make a Trendy but Illegal Therapy - Inverse - June 27th, 2017 [June 27th, 2017]
- The war on drugs is back. Will psychedelic drug research survive? - The Verge - June 29th, 2017 [June 29th, 2017]
- Tune in, Turn on, Stay in School - Study Breaks - July 2nd, 2017 [July 2nd, 2017]
- Cannabist Show: He's psychedelic comedian Shane Mauss - The Cannabist - July 2nd, 2017 [July 2nd, 2017]
- The brain on DMT: mapping the psychedelic drug's effects - Wired.co.uk - July 3rd, 2017 [July 3rd, 2017]
- Psychedelics Could Help Asia's Mental Health Care, But Stigma Remains Roadblock - TheFix.com - July 3rd, 2017 [July 3rd, 2017]
- Is LSD the new coffee? - FactorDaily - July 4th, 2017 [July 4th, 2017]
- My grandfather was a death row doctor. He tested psychedelic drugs on Texas inmates. - Texas Tribune - July 5th, 2017 [July 5th, 2017]
- About Us | Trusted News Source for Psychedelic Research ... - July 6th, 2017 [July 6th, 2017]
- Do Psychedelic Drugs Cause the 'Prophetic Effect'? - Breaking Israel News - July 11th, 2017 [July 11th, 2017]
- Are psychedelics the new medical marijuana? - WTSP 10 News - July 14th, 2017 [July 14th, 2017]
- Psychiatrists Say Cannabis Medicine Has Psychedelic Properties - The Marijuana Times - July 15th, 2017 [July 15th, 2017]
- Can Psychedelics Be Therapy? Allow Research to Find Out - New York Times - July 17th, 2017 [July 17th, 2017]
- Countdown To (Legalized) Ecstasy! Rick Doblin, MAPS, & the Psychedelic Renaissance [Podcast] - Reason (blog) - July 20th, 2017 [July 20th, 2017]
- Should We Reclassify Marijuana as a Hallucinogen? - Big Think - July 20th, 2017 [July 20th, 2017]
- Do You Take Drugs at Festivals? This Initiative is Working on Keeping You Safe - PoliticalCritique.org - July 20th, 2017 [July 20th, 2017]
- Psychedelic drugs could tackle depression in a way that antidepressants can't - INSIDER - July 22nd, 2017 [July 22nd, 2017]
- Psychedelic Shine takes a trip to the skies in Boulder - Boulder Daily Camera - July 22nd, 2017 [July 22nd, 2017]
- Reasons to Consider Trying Psychedelics - FoxWeekly - July 27th, 2017 [July 27th, 2017]
- Psychedelics and Normality - HuffPost - July 27th, 2017 [July 27th, 2017]
- New book about psychedelics and weird human experiences - Boing Boing - July 27th, 2017 [July 27th, 2017]
- Scientists Want You to Give Them Money to Study ... - July 29th, 2017 [July 29th, 2017]
- What Has Awe Done for Me Lately? - HuffPost - August 1st, 2017 [August 1st, 2017]
- For children, it's beyond psychedelics - The Hans India - The Hans India - August 1st, 2017 [August 1st, 2017]
- Expanding consciousness - 48 Hills - August 2nd, 2017 [August 2nd, 2017]
- THE FUTURE OF PSYCHEDELICS: Are LSD and Mushrooms The New Prozac? - Dope Magazine - August 5th, 2017 [August 5th, 2017]
- Psychedelic drugs saved my life. So why aren't they prescribed? - Wired.co.uk - August 9th, 2017 [August 9th, 2017]
- LSD as therapy: How scientists are reclaiming psychedelics ... - August 9th, 2017 [August 9th, 2017]
- The foundation of Western philosophy is probably rooted in psychedelics - Quartz - August 12th, 2017 [August 12th, 2017]
- Crazy Enough to be Correct - HuffPost - August 15th, 2017 [August 15th, 2017]